#nonsmallcell search results

Do not forget the role of adding @immunotherapy to #chemotherapy for #nonsmallcell #lungcancer in every #pdl1 subgroups even during #covid19 by @MP_3855 @LungSummit

gbanna74's tweet image. Do not forget the role of adding @immunotherapy to #chemotherapy for #nonsmallcell #lungcancer in every #pdl1 subgroups even during #covid19 by @MP_3855  @LungSummit

At @ASCO, scientists from MSK presented promising results on three different targeted therapies — one for #smallcell #lungcancer and two for #nonsmallcell lung cancer. Read more from thoracic medical oncologists @charlesrudin, @HelenaYu923, and @ChaftJamie:…

MSKCancerCenter's tweet image. At @ASCO, scientists from MSK presented promising results on three different targeted therapies — one for #smallcell #lungcancer and two for #nonsmallcell lung cancer.

Read more from thoracic medical oncologists @charlesrudin, @HelenaYu923, and @ChaftJamie:…

A study led by researchers at @HarvardChanSPH followed 5,594 patients with #NonSmallCell #LungCancer to investigate how #SmokingCessation was associated to #SurvivalRates. #CurrentSmokers had 68% higher mortality & #FormerSmokers had 26% higher mortality. zurl.co/SgyC


Phase II trial of Tumor-Infiltrating Lymphocyte (TIL) therapy (Lifileucel) in Advanced Non-Small Cell Lung Cancer post Immunotherapy with or without chemotherapy - @DrJNaidoo oncodaily.com/44062.html #Cancer #Cyclophosphamide #NonSmallCell #LungCancer #OncoDaily #Oncology

oncodaily's tweet image. Phase II trial of Tumor-Infiltrating Lymphocyte (TIL) therapy (Lifileucel) in Advanced Non-Small Cell Lung Cancer post Immunotherapy with or without chemotherapy - @DrJNaidoo
oncodaily.com/44062.html

#Cancer #Cyclophosphamide #NonSmallCell #LungCancer #OncoDaily #Oncology

Residual #ctDNA after #Treatment predicts early relapse in patients with early-stage #NonSmallCell #LungCancer: 1⃣This may help identify patients who need further therapeutic intervention!👇 bit.ly/3ak5pQn #LiquidBiopsy #cfDNA

davidhenrymd's tweet image. Residual #ctDNA after #Treatment predicts early relapse in patients with early-stage #NonSmallCell #LungCancer:
1⃣This may help identify patients who need further therapeutic intervention!👇
bit.ly/3ak5pQn
#LiquidBiopsy #cfDNA

#ROSE confirmed #nonsmallcell carcinoma of the #lung in a mass suspected for TB,biopsy sent later on for intraoperative consult showed extensive black pigmentation (Anthracosis) and a couple of tumor cells seen on histology sections #pathology #cancer #diagnosticmedicine

KAlgashaamy's tweet image. #ROSE confirmed #nonsmallcell carcinoma of the #lung in a mass suspected for TB,biopsy sent later on for intraoperative consult showed extensive black pigmentation (Anthracosis) and a couple of tumor cells seen on histology sections #pathology #cancer #diagnosticmedicine
KAlgashaamy's tweet image. #ROSE confirmed #nonsmallcell carcinoma of the #lung in a mass suspected for TB,biopsy sent later on for intraoperative consult showed extensive black pigmentation (Anthracosis) and a couple of tumor cells seen on histology sections #pathology #cancer #diagnosticmedicine

Intriguingly many thoracic phase 3 randomized trials evaluating immune Checkpoint Inhibitors lack robustness with SIFI also in #nonsmallcell #lungcancer as well as #mesothelioma trials doi:10.1001/jamanetworkopen.2022.1490 doi:10.1001/jamanetworkopen.2020.17675 @gecp_org

Migueln16468689's tweet image. Intriguingly many thoracic phase 3 randomized trials   evaluating immune Checkpoint Inhibitors lack robustness with SIFI also in #nonsmallcell #lungcancer as well as #mesothelioma trials doi:10.1001/jamanetworkopen.2022.1490
doi:10.1001/jamanetworkopen.2020.17675 @gecp_org

#LIPS prognostic tool for high #pdl1 #nonsmallcell #lungcancer treated with #Immunotherapy 1. validated #NLR cutoff = 4; 2. by adding pretreatment steroids and PS 2, 40% favourable-risk patients with #IO alone. @Alfdoc2 @ACortelliniMD @OncoAlert #LCSM sciencedirect.com/science/articl…

gbanna74's tweet image. #LIPS prognostic tool for high #pdl1 #nonsmallcell #lungcancer treated with #Immunotherapy 1. validated #NLR cutoff = 4; 2. by adding pretreatment steroids and PS 2, 40% favourable-risk patients with #IO alone. @Alfdoc2 @ACortelliniMD @OncoAlert #LCSM sciencedirect.com/science/articl…

There is biological rationale and enough clinical evidence for Peripheral Blood Cell – derived #Inflammatory indices and related #Prognostic Scores in Patients with advanced #nonsmallcell #lungcancer treated with #immunotherapy #LCSM rdcu.be/cXP91 @OncoViews

gbanna74's tweet image. There is biological rationale and enough clinical evidence for Peripheral Blood Cell – derived #Inflammatory indices and related #Prognostic Scores in Patients with advanced #nonsmallcell #lungcancer treated with #immunotherapy #LCSM rdcu.be/cXP91 @OncoViews

Dr. Chaft discusses second-line treatment for patients with NSCLC. Free online CME expiring on Friday. Don’t miss it! buff.ly/2N1TN6o #NSCLC #CME #nonsmallcell #lungcancer #lung #cancer #pulmonology #pulmonologist #oncology #oncologist

i3health's tweet image. Dr. Chaft discusses second-line treatment for patients with NSCLC. Free online CME expiring on Friday. Don’t miss it! buff.ly/2N1TN6o

#NSCLC #CME #nonsmallcell #lungcancer #lung #cancer #pulmonology #pulmonologist #oncology #oncologist

🚨 LIVE WEBINAR with Dr. Geoffrey Liu & Dr. Jeffrey Habert – Jan. 20th @ 7pm EST 🚨 By the end of their presentation, you will be able to distinguish between #LungCancer symptoms and other diagnoses. Save the date + register today ➡️ therounds.com/liu/home #NonSmallCell

TheRounds's tweet image. 🚨 LIVE WEBINAR with Dr. Geoffrey Liu & Dr. Jeffrey Habert – Jan. 20th @ 7pm EST 🚨

By the end of their presentation, you will be able to distinguish between #LungCancer symptoms and other diagnoses. Save the date + register today ➡️ therounds.com/liu/home #NonSmallCell

#KRAS mutation is found in 15-25% #nonsmallcell #lungcancer (#NSCLC). Even with the high rates in #NSCLC, #treatment options are limited. Thankfully, #research is making strides for #KRAS #patients. Read here: bit.ly/3hqiFD3

lcfamerica's tweet image. #KRAS mutation is found in 15-25% #nonsmallcell #lungcancer (#NSCLC). Even with the high rates in #NSCLC, #treatment options are limited. Thankfully, #research is making strides for #KRAS #patients. Read here: bit.ly/3hqiFD3

Latest in #research – Imfinzi increases 5-year survival to 43% in #patients with stage III #nonsmallcell #lungcancer! #NSCLC #researchsaveslives bit.ly/3AEL8ha

lcfamerica's tweet image. Latest in #research – Imfinzi increases 5-year survival to 43% in #patients with stage III #nonsmallcell #lungcancer! #NSCLC #researchsaveslives bit.ly/3AEL8ha

The @FDA_Drug_Info approves a combination #therapy for some #nonsmallcell #lungcancer #patients! Read more about this #treatment advancement here: bit.ly/2ByDGtQ

lcfamerica's tweet image. The @FDA_Drug_Info approves a combination #therapy for some #nonsmallcell #lungcancer #patients! Read more about this #treatment advancement here: bit.ly/2ByDGtQ

NOW ONLINE: Two butyrate-producing bacteria are associated with longer #progressionfreesurvival in chemo-refractory #colorectalcancer and #nonsmallcell #lungcancer patients 🔓OPEN ACCESS ➡️doi.org/10.1002/ijc.34… Giulia Martini, Davide Ciardiello and collaborators

IntJCanc's tweet image. NOW ONLINE: Two butyrate-producing bacteria are associated with longer #progressionfreesurvival in chemo-refractory #colorectalcancer and #nonsmallcell #lungcancer patients

🔓OPEN ACCESS
➡️doi.org/10.1002/ijc.34…
Giulia Martini, Davide Ciardiello and collaborators

Merck Discontinues the P-III (KEYLYNK-008) Study of Keytruda (pembrolizumab) + Lynparza (olaparib) for Metastatic Squamous NSCLC #merck #keytruda #nonsmallcell #lungcancer #clinicaltrials #keylynk008 #lynparza #datamonitoring #committee #carboplatin pharmashots.com/16511/merck-di…

Pharmashot's tweet image. Merck Discontinues the P-III (KEYLYNK-008) Study of Keytruda (pembrolizumab) + Lynparza (olaparib) for Metastatic Squamous NSCLC 
#merck #keytruda #nonsmallcell #lungcancer #clinicaltrials #keylynk008 #lynparza #datamonitoring #committee #carboplatin 
pharmashots.com/16511/merck-di…

At @ASCO, scientists from MSK presented promising results on three different targeted therapies — one for #smallcell #lungcancer and two for #nonsmallcell lung cancer. Read more from thoracic medical oncologists @charlesrudin, @HelenaYu923, and @ChaftJamie:…

MSKCancerCenter's tweet image. At @ASCO, scientists from MSK presented promising results on three different targeted therapies — one for #smallcell #lungcancer and two for #nonsmallcell lung cancer.

Read more from thoracic medical oncologists @charlesrudin, @HelenaYu923, and @ChaftJamie:…

🧵 Akeso, Summit's PD-1/VEGF bispecific records another pivotal study win in NSCLC #Ivonescimab #NonSmallCell #Akeso #PdVegf #Keytruda #Summit #Pharmacotherapy #Combined #Safety


🧵 Daiichi Sankyo and Merck Achieve Phase III Success with HER3-Targeted ADC in Lung Cancer #PatritumabDeruxtecan #Her3TargetedAdc #NonSmallCell #PhaseIiiTrial #HerthenaLung02 #DaiichiSankyo #MerckCo


No results for "#nonsmallcell"

Do not forget the role of adding @immunotherapy to #chemotherapy for #nonsmallcell #lungcancer in every #pdl1 subgroups even during #covid19 by @MP_3855 @LungSummit

gbanna74's tweet image. Do not forget the role of adding @immunotherapy to #chemotherapy for #nonsmallcell #lungcancer in every #pdl1 subgroups even during #covid19 by @MP_3855  @LungSummit

At @ASCO, scientists from MSK presented promising results on three different targeted therapies — one for #smallcell #lungcancer and two for #nonsmallcell lung cancer. Read more from thoracic medical oncologists @charlesrudin, @HelenaYu923, and @ChaftJamie:…

MSKCancerCenter's tweet image. At @ASCO, scientists from MSK presented promising results on three different targeted therapies — one for #smallcell #lungcancer and two for #nonsmallcell lung cancer.

Read more from thoracic medical oncologists @charlesrudin, @HelenaYu923, and @ChaftJamie:…

Phase II trial of Tumor-Infiltrating Lymphocyte (TIL) therapy (Lifileucel) in Advanced Non-Small Cell Lung Cancer post Immunotherapy with or without chemotherapy - @DrJNaidoo oncodaily.com/44062.html #Cancer #Cyclophosphamide #NonSmallCell #LungCancer #OncoDaily #Oncology

oncodaily's tweet image. Phase II trial of Tumor-Infiltrating Lymphocyte (TIL) therapy (Lifileucel) in Advanced Non-Small Cell Lung Cancer post Immunotherapy with or without chemotherapy - @DrJNaidoo
oncodaily.com/44062.html

#Cancer #Cyclophosphamide #NonSmallCell #LungCancer #OncoDaily #Oncology

There is biological rationale and enough clinical evidence for Peripheral Blood Cell – derived #Inflammatory indices and related #Prognostic Scores in Patients with advanced #nonsmallcell #lungcancer treated with #immunotherapy #LCSM rdcu.be/cXP91 @OncoViews

gbanna74's tweet image. There is biological rationale and enough clinical evidence for Peripheral Blood Cell – derived #Inflammatory indices and related #Prognostic Scores in Patients with advanced #nonsmallcell #lungcancer treated with #immunotherapy #LCSM rdcu.be/cXP91 @OncoViews

These dynamic RNA signals were specific to histology and stage #nonsmallcell #smallcell #lungcancer #mirna #pirna #lncrna #mrna #isomiR #tRF #trna

sinanugur's tweet image. These dynamic RNA signals were specific to histology and stage #nonsmallcell #smallcell #lungcancer #mirna #pirna #lncrna #mrna #isomiR #tRF #trna

#LIPS prognostic tool for high #pdl1 #nonsmallcell #lungcancer treated with #Immunotherapy 1. validated #NLR cutoff = 4; 2. by adding pretreatment steroids and PS 2, 40% favourable-risk patients with #IO alone. @Alfdoc2 @ACortelliniMD @OncoAlert #LCSM sciencedirect.com/science/articl…

gbanna74's tweet image. #LIPS prognostic tool for high #pdl1 #nonsmallcell #lungcancer treated with #Immunotherapy 1. validated #NLR cutoff = 4; 2. by adding pretreatment steroids and PS 2, 40% favourable-risk patients with #IO alone. @Alfdoc2 @ACortelliniMD @OncoAlert #LCSM sciencedirect.com/science/articl…

#ROSE confirmed #nonsmallcell carcinoma of the #lung in a mass suspected for TB,biopsy sent later on for intraoperative consult showed extensive black pigmentation (Anthracosis) and a couple of tumor cells seen on histology sections #pathology #cancer #diagnosticmedicine

KAlgashaamy's tweet image. #ROSE confirmed #nonsmallcell carcinoma of the #lung in a mass suspected for TB,biopsy sent later on for intraoperative consult showed extensive black pigmentation (Anthracosis) and a couple of tumor cells seen on histology sections #pathology #cancer #diagnosticmedicine
KAlgashaamy's tweet image. #ROSE confirmed #nonsmallcell carcinoma of the #lung in a mass suspected for TB,biopsy sent later on for intraoperative consult showed extensive black pigmentation (Anthracosis) and a couple of tumor cells seen on histology sections #pathology #cancer #diagnosticmedicine

The @FDA_Drug_Info approves a combination #therapy for some #nonsmallcell #lungcancer #patients! Read more about this #treatment advancement here: bit.ly/2ByDGtQ

lcfamerica's tweet image. The @FDA_Drug_Info approves a combination #therapy for some #nonsmallcell #lungcancer #patients! Read more about this #treatment advancement here: bit.ly/2ByDGtQ

Competing Immune #biomarkers in the Selection of First-Line Therapy in #NonSmallCell #LungCancer; Khaled A Tolba; Oncology & Hematology Review. 2018;14(2):67–9; Full free-to-access article available here: doi.org/10.17925/OHR.2… #ImmuneCheckpointInhibitors #cancers #melanoma

touchONCOLOGY's tweet image. Competing Immune #biomarkers in the Selection of First-Line Therapy in #NonSmallCell #LungCancer; Khaled A Tolba; Oncology & Hematology Review. 2018;14(2):67–9; Full free-to-access article available here: doi.org/10.17925/OHR.2…
#ImmuneCheckpointInhibitors  #cancers #melanoma

#KRAS mutation is found in 15-25% #nonsmallcell #lungcancer (#NSCLC). Even with the high rates in #NSCLC, #treatment options are limited. Thankfully, #research is making strides for #KRAS #patients. Read here: bit.ly/3hqiFD3

lcfamerica's tweet image. #KRAS mutation is found in 15-25% #nonsmallcell #lungcancer (#NSCLC). Even with the high rates in #NSCLC, #treatment options are limited. Thankfully, #research is making strides for #KRAS #patients. Read here: bit.ly/3hqiFD3

Latest in #research – Imfinzi increases 5-year survival to 43% in #patients with stage III #nonsmallcell #lungcancer! #NSCLC #researchsaveslives bit.ly/3AEL8ha

lcfamerica's tweet image. Latest in #research – Imfinzi increases 5-year survival to 43% in #patients with stage III #nonsmallcell #lungcancer! #NSCLC #researchsaveslives bit.ly/3AEL8ha

NOW ONLINE: Two butyrate-producing bacteria are associated with longer #progressionfreesurvival in chemo-refractory #colorectalcancer and #nonsmallcell #lungcancer patients 🔓OPEN ACCESS ➡️doi.org/10.1002/ijc.34… Giulia Martini, Davide Ciardiello and collaborators

IntJCanc's tweet image. NOW ONLINE: Two butyrate-producing bacteria are associated with longer #progressionfreesurvival in chemo-refractory #colorectalcancer and #nonsmallcell #lungcancer patients

🔓OPEN ACCESS
➡️doi.org/10.1002/ijc.34…
Giulia Martini, Davide Ciardiello and collaborators

Dr. Chaft discusses second-line treatment for patients with NSCLC. Free online CME expiring on Friday. Don’t miss it! buff.ly/2N1TN6o #NSCLC #CME #nonsmallcell #lungcancer #lung #cancer #pulmonology #pulmonologist #oncology #oncologist

i3health's tweet image. Dr. Chaft discusses second-line treatment for patients with NSCLC. Free online CME expiring on Friday. Don’t miss it! buff.ly/2N1TN6o

#NSCLC #CME #nonsmallcell #lungcancer #lung #cancer #pulmonology #pulmonologist #oncology #oncologist

🚨 LIVE WEBINAR with Dr. Geoffrey Liu & Dr. Jeffrey Habert – Jan. 20th @ 7pm EST 🚨 By the end of their presentation, you will be able to distinguish between #LungCancer symptoms and other diagnoses. Save the date + register today ➡️ therounds.com/liu/home #NonSmallCell

TheRounds's tweet image. 🚨 LIVE WEBINAR with Dr. Geoffrey Liu & Dr. Jeffrey Habert – Jan. 20th @ 7pm EST 🚨

By the end of their presentation, you will be able to distinguish between #LungCancer symptoms and other diagnoses. Save the date + register today ➡️ therounds.com/liu/home #NonSmallCell

Residual #ctDNA after #Treatment predicts early relapse in patients with early-stage #NonSmallCell #LungCancer: 1⃣This may help identify patients who need further therapeutic intervention!👇 bit.ly/3ak5pQn #LiquidBiopsy #cfDNA

davidhenrymd's tweet image. Residual #ctDNA after #Treatment predicts early relapse in patients with early-stage #NonSmallCell #LungCancer:
1⃣This may help identify patients who need further therapeutic intervention!👇
bit.ly/3ak5pQn
#LiquidBiopsy #cfDNA

Intriguingly many thoracic phase 3 randomized trials evaluating immune Checkpoint Inhibitors lack robustness with SIFI also in #nonsmallcell #lungcancer as well as #mesothelioma trials doi:10.1001/jamanetworkopen.2022.1490 doi:10.1001/jamanetworkopen.2020.17675 @gecp_org

Migueln16468689's tweet image. Intriguingly many thoracic phase 3 randomized trials   evaluating immune Checkpoint Inhibitors lack robustness with SIFI also in #nonsmallcell #lungcancer as well as #mesothelioma trials doi:10.1001/jamanetworkopen.2022.1490
doi:10.1001/jamanetworkopen.2020.17675 @gecp_org

Loading...

Something went wrong.


Something went wrong.


United States Trends